Metabolomx is a biotechnology startup that has developed cutting-edge breath analysis technology to detect lung cancer with high accuracy, pinpoint subtypes, and advance early diagnosis with superior sensitivity. Founded in 2010, the company's innovative solution has garnered attention for its potential to revolutionize the field of healthcare. Utilizing the first generation of its system, The Cleveland Clinic conducted a study involving 237 subjects and presented its results at the American College of Chest Physicians conference in November 2010.
The findings were impressive, showing an 81% accuracy rate in lung cancer detection, equivalent to the current gold standard of CT scans. Moreover, the breath exam displayed the capability to identify various lung cancer subtypes, including small cell, adenocarcinoma, and squamous cell. Notably, the latest generation of the Metabolomx sensor is being tested by The Cleveland Clinic, showcasing an astounding 100 times more sensitivity than the initial version used in the study.
In October 24, 2011, the company received a notable $1.14M grant investment, signifying investor confidence in the potential of its groundbreaking technology. This investment provides a strong foundation for Metabolomx to further develop its innovative solutions and make significant strides in the fight against lung cancer.
